47045-BDI-Z-UNDP-1 The Global Fund to Fight AIDS, Tuberculosis and Malaria <narrative xml:lang="en">Programme to Accelerate the Reduction of Transmission of the HIV and Tuberculosis Epidemic and to Improve Malaria Management in Burundi (PACTEAPEC) - Burundi (01-Jan-2024-31-Dec-2026)</narrative> Burundi, Multicomponent, United Nations Development Programme (UNDP Burundi)This program has the following goals: Contribuer à mettre fin aux épidémies du VIH, des IST, des Hépatites virales comme ménace pour la santé publique d'ici 2030 au Burundi, en Réduisant les nouvelles infections , les décès et la discrimination/stigmatisation // Contribute to ending the epidemics of HIV, STIs and viral hepatitis as a public health threat by 2030 in Burundi, by reducing new infections, deaths and discrimination/stigmatization.. Mettre fin à la tendance épidémique de la tuberculose au Burundi afin de libérer la population du fardeau lié à la TB et ses comorbidité pour sa participation au dévelopment du pays // Put an end to the epidemic trend of tuberculosis in Burundi in order to free the population from the burden of TB and its co-morbidities and allow them to participate in the country's development.. Doter à la population vivant sur le territoire burundais des outils et services les plus efficaces de lutte contre le Paludisme (mission) // Provide the population living in Burundi with the most effective tools and services to fight malaria (mission). Contribuer à la réduction de la mortalité, des handicaps et invalidités évitables par l’offre et l’utilisation des services de santé de qualité à toute la population qui en a besoin // Contribute to the reduction of avoidable mortality and disabilities through the provision and use of quality health services to the entire population in need.. The objectives of this program are: Résultat d’Impact 1 : D’ici 2027, les nouvelles infections à VIH/IST/HV sont réduites d’au moins 70 %, en particulier pour les populations les plus exposées // Impact Outcome 1: By 2027, new HIV/STI/Hep infections are reduced by at least 70%, particularly for most-at-risk populations.. Résultat d’Impact 2 : D’ici 2027, la morbi-mortalité liée au VIH /IST est réduite d’au moins 70% et d’au moins 65% des décès liés aux hépatites virales // Impact Outcome 2: By 2027, HIV/STI-related morbidity and mortality is reduced by at least 70% and viral hepatitis-related deaths by at least 65%.. Résultat d’impact 3 : D’ici 2027, l’environnement lié aux droits humains et au genre est amélioré pour lever les barrières de l’accès aux services de prévention de prise e charge du VIH, des IST et des HV y compris la suppression des coûts catastrophiques // Impact outcome 3: By 2027, the human rights and gender environment is improved to remove barriers to accessing HIV, STI and Hepatitis prevention and care services, including the elimination of catastrophic costs.. Résultat d’impact 4 : D’ici 2027, la gouvernance est renforcée pour maintenir les performances, l’efficience, la redevabilité et la durabilité de la réponse nationale au VIH/IST/HV sous le leadership du CNLS // Impact outcome 4: By 2027, governance is strengthened to maintain the performance, efficiency, accountability and sustainability of the national response to HIV/STI/Hep under the leadership of the CNLS.. D'ici 2027, contribuer à la réduction de la morbidité et de la mortalité due à la tuberculose ainsi que les coûts catastrophique ainsi que la réduction de 75% des décès (par rapport à 2015) et 50% de l'incidence ( par rapport à 2015) // By 2027, contribute to the reduction of morbidity and mortality due to tuberculosis as well as catastrophic costs, with a 75% reduction in deaths (compared to 2015) and a 50% reduction in incidence (compared to 2015).. Réduire de 60% la morbidité et à 0% la mortalité liée au Paludisme au Burundi // Reduce malaria-related morbidity by 60% and mortality to 0% in Burundi. D'ici 2026, le score global de complétude et promptitude de la qualité des données du système d'information sanitaire de routine passe respectivement de 81% à 92% et de 56% à 75% // By 2026, the overall score for completeness and timeliness of routine health information system data quality will rise from 81% to 92% and from 56% to 75% respectively. The Global Fund to Fight AIDS, Tuberculosis and Malaria The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme United Nations Development Programme United Nations Development Programme The Global Fund to Fight AIDS, Tuberculosis and Malaria The Global Fund to Fight AIDS Tuberculosis and Malaria Communications Web Team +41 58 791 1700 website@theglobalfund.org https://www.theglobalfund.org The Global Fund to Fight AIDS, Tuberculosis and Malaria, Global Health Campus, Chemin du Pommier 40, 1218 Grand-Saconnex, Geneva, Switzerland The Global Fund to Fight AIDS Tuberculosis and Malaria Grant Management Division Gilles, CESARI Fund Portfolio Manager +41 58 791 1700 gilles.cesari@theglobalfund.org https://www.theglobalfund.org The Global Fund to Fight AIDS, Tuberculosis and Malaria, Global Health Campus, Chemin du Pommier 40, 1218 Grand-Saconnex, Geneva, Switzerland The Global Fund to Fight AIDS Tuberculosis and Malaria Communications Web Team +41 58 791 1700 website@theglobalfund.org https://www.theglobalfund.org The Global Fund to Fight AIDS, Tuberculosis and Malaria, Global Health Campus, Chemin du Pommier 40, 1218 Grand-Saconnex, Geneva, Switzerland Burundi HIV Malaria Multicomponent RSSH Tuberculosis HIV -> Differentiated HIV Testing Services -> Facility-based testing for adolescent girls and young women (AGYW) and their male sexual partners programs HIV -> Differentiated HIV Testing Services -> Facility-based testing for key population (KP) programs HIV -> Differentiated HIV Testing Services -> Facility-based testing outside of key population (KP) and adolescent girls and young women (AGYW) programs HIV -> Differentiated HIV Testing Services -> Self-testing for KP programs HIV -> Elimination of vertical transmission of HIV, syphilis and hepatitis B -> Early infant diagnosis and follow-up HIV testing for exposed infants HIV -> Elimination of vertical transmission of HIV, syphilis and hepatitis B -> Integrated testing of pregnant women for HIV, syphilis and hepatitis B HIV -> Elimination of vertical transmission of HIV, syphilis and hepatitis B -> Post-natal infant prophylaxis HIV -> Elimination of vertical transmission of HIV, syphilis and hepatitis B -> Prevention of incident HIV among pregnant and breastfeeding women HIV -> Elimination of vertical transmission of HIV, syphilis and hepatitis B -> Retention support for pregnant and breastfeeding women (facility and community) HIV -> Prevention package for adolescent girls and young women (AGYW) and male sexual partners in high HIV incidence settings -> Sexual and reproductive health services, including STIs, hepatitis, post-violence care for AGYW and male sexual partners in high HIV incidence settings HIV -> Prevention package for men who have sex with men (MSM) and their sexual partners -> Community empowerment for MSM HIV -> Prevention package for men who have sex with men (MSM) and their sexual partners -> Condom and lubricant programing for MSM HIV -> Prevention package for men who have sex with men (MSM) and their sexual partners -> HIV prevention communication, information and demand creation for MSM HIV -> Prevention package for men who have sex with men (MSM) and their sexual partners -> Pre-exposure prophylaxis (PrEP) programing for MSM HIV -> Prevention package for men who have sex with men (MSM) and their sexual partners -> Sexual and reproductive health services, including STIs, hepatitis, post-violence care for MSM HIV -> Prevention package for other vulnerable populations (OVP) -> Condom and lubricant programing for OVP HIV -> Prevention package for other vulnerable populations (OVP) -> Sexual and reproductive health services, including STIs, hepatitis, post-violence care for OVP HIV -> Prevention package for people in prisons and other closed settings -> Condom and lubricant programing for prisoners HIV -> Prevention package for people who use drugs (PUD) and their sexual partners -> Community empowerment for PUD HIV -> Prevention package for people who use drugs (PUD) and their sexual partners -> Condom and lubricant programing for PUD HIV -> Prevention package for people who use drugs (PUD) and their sexual partners -> HIV prevention communication, information and demand creation for PUD HIV -> Prevention package for people who use drugs (PUD) and their sexual partners -> Opioid substitution therapy and other medically assisted drug dependence treatment for PWID HIV -> Prevention package for people who use drugs (PUD) and their sexual partners -> Pre-exposure prophylaxis (PrEP) programing for PUD HIV -> Prevention package for people who use drugs (PUD) and their sexual partners -> Sexual and reproductive health services, including STIs, hepatitis, post-violence care for PUD HIV -> Prevention package for sex workers, their clients and other sexual partners -> Community empowerment for sex workers HIV -> Prevention package for sex workers, their clients and other sexual partners -> Condom and lubricant programing for sex workers HIV -> Prevention package for sex workers, their clients and other sexual partners -> HIV prevention communication, information and demand creation for sex workers HIV -> Prevention package for sex workers, their clients and other sexual partners -> Pre-exposure prophylaxis (PrEP) programing for sex workers HIV -> Prevention package for sex workers, their clients and other sexual partners -> Sexual and reproductive health services, including STIs, hepatitis, post-violence care for sex workers HIV -> Reducing human rights-related barriers to HIV/TB services -> Community mobilization and advocacy for human rights HIV -> Reducing human rights-related barriers to HIV/TB services -> Increasing access to justice (HIV/TB) HIV -> Reducing human rights-related barriers to HIV/TB services -> Legal literacy (“Know Your Rights”) (HIV/TB) HIV -> Treatment, care and support -> Diagnosis and management of advanced disease (adults and children) HIV -> Treatment, care and support -> HIV treatment and differentiated service delivery - adults (15 and above) HIV -> Treatment, care and support -> HIV treatment and differentiated service delivery - children (under 15) HIV -> Treatment, care and support -> Integrated management of common co-infections and co-morbidities (adults and children) HIV -> Treatment, care and support -> Treatment monitoring - Drug resistance HIV -> Treatment, care and support -> Treatment monitoring - Viral load and antiretroviral (ARV) toxicity Malaria -> Case management -> Epidemic preparedness Malaria -> Case management -> Facility-based treatment Malaria -> Case management -> Integrated community case management (iCCM) Malaria -> Specific prevention interventions (SPI) -> Intermittent preventive treatment (IPT) - In pregnancy Malaria -> Specific prevention interventions (SPI) -> Perennial malaria chemoprevention (PMC) Malaria -> Specific prevention interventions (SPI) -> Removing human rights and gender-related barriers to specific prevention interventions Malaria -> Specific prevention interventions (SPI) -> Social and behavior change (SBC) (SPI) Malaria -> Vector control -> Indoor residual spraying (IRS) Malaria -> Vector control -> Insecticide treated nets (ITNs) - Continuous distribution: ANC Malaria -> Vector control -> Insecticide treated nets (ITNs) - Continuous distribution: community-based Malaria -> Vector control -> Insecticide treated nets (ITNs) - Continuous distribution: EPI Malaria -> Vector control -> Insecticide treated nets (ITNs) - Mass campaign: universal Malaria -> Vector control -> Social and behavior change (SBC) (Vector control) Multicomponent -> Program management -> Coordination and management of national disease control programs Multicomponent -> Program management -> Grant management RSSH -> RSSH: Monitoring and evaluation systems -> Analyses, evaluations, reviews and data use RSSH -> RSSH: Monitoring and evaluation systems -> Data quality RSSH -> RSSH: Monitoring and evaluation systems -> Routine reporting RSSH -> RSSH: Monitoring and evaluation systems -> RSSH/PP: Surveillance for priority epidemic-prone diseases and events RSSH -> RSSH: Monitoring and evaluation systems -> Surveys Tuberculosis -> Collaboration with other providers and sectors -> Collaboration with other programs/sectors Tuberculosis -> Drug-resistant (DR)-TB diagnosis, treatment and care -> DR-TB diagnosis/drug susceptibility testing (DST) Tuberculosis -> Drug-resistant (DR)-TB diagnosis, treatment and care -> DR-TB treatment, care and support Tuberculosis -> Key and vulnerable populations (KVP) - TB/DR-TB -> KVP - Children and adolescents Tuberculosis -> Key and vulnerable populations (KVP) - TB/DR-TB -> KVP - Miners and mining communities Tuberculosis -> Key and vulnerable populations (KVP) - TB/DR-TB -> KVP - Mobile population (migrants/refugees/IDPs) Tuberculosis -> Key and vulnerable populations (KVP) - TB/DR-TB -> KVP - Others Tuberculosis -> Key and vulnerable populations (KVP) - TB/DR-TB -> KVP - People in prisons/jails/detention centers Tuberculosis -> Key and vulnerable populations (KVP) - TB/DR-TB -> KVP - Urban poor/slum dwellers Tuberculosis -> TB diagnosis, treatment and care -> TB screening and diagnosis Tuberculosis -> TB diagnosis, treatment and care -> TB treatment, care and support Tuberculosis -> TB/DR-TB Prevention -> Infection prevention and control (IPC) Tuberculosis -> TB/HIV -> TB/HIV - Community care delivery Tuberculosis -> TB/HIV -> TB/HIV - Prevention Tuberculosis -> TB/HIV -> TB/HIV - Screening, testing and diagnosis Tuberculosis -> TB/HIV -> TB/HIV - Treatment and care 19294693.12 66960910.75 23093581.69 77587759.00 Global Fund Commitment to BDI-Z-UNDPP01. Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme (UNDP Burundi) 14885730.00 Global Fund Commitment to BDI-Z-UNDPP01. Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme (UNDP Burundi) -409379.00 Global Fund Commitment to BDI-Z-UNDPP01. Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme (UNDP Burundi) 10629139.00 Global Fund disbursement to BDI-Z-UNDPP01. Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme (UNDP Burundi) 9136513.00 Global Fund disbursement to BDI-Z-UNDPP01. Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme (UNDP Burundi) 31955898.00 Global Fund disbursement to BDI-Z-UNDPP01. Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme (UNDP Burundi) 3199377.00 Global Fund disbursement to BDI-Z-UNDPP01. Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme (UNDP Burundi) 36085969.00 Global Fund disbursement to BDI-Z-UNDPP01. Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme (UNDP Burundi) <narrative xml:lang="en">Grant page on the data portal of the Global Fund.</narrative> An overview of a grant over it's lifetime. <narrative xml:lang="en">Grant terms and conditions.</narrative> General terms and conditions which apply to Global Fund grants. <narrative xml:lang="en">Coverage / Output indicators targets and results for BDI-Z-UNDPP01</narrative> <narrative xml:lang="en">Treatment success rate of RR-TB and/or MDR-TB: Percentage of patients with RR and/or MDR-TB successfully treated</narrative> <narrative xml:lang="en">Number of people in contact with TB patients who began preventive therapy</narrative> <narrative xml:lang="en">Proportion of confirmed malaria cases that received first-line antimalarial treatment at public sector health facilities</narrative> <narrative xml:lang="en">TBDT-1 other Number of women reported with all forms of tuberculosis (i.e. bacteriologically confirmed and clinically diagnosed); *includes only new patients and relapses</narrative> <narrative xml:lang="en">Number of insecticide-treated nets distributed to targeted risk groups through continuous distribution</narrative> <narrative xml:lang="en">Percentage of people with confirmed RR-TB and/or MDR-TB that began second-line treatment</narrative> <narrative xml:lang="en">Percentage of children (under 15) on ART among all children living with HIV at the end of the reporting period</narrative> <narrative xml:lang="en">TBDT-1 other Number of patients under 15 with all forms of tuberculosis (i.e. bacteriologically confirmed and clinically diagnosed); *includes only new patients and relapses.</narrative> <narrative xml:lang="en">Number of people with confirmed RR-TB and/or MDR-TB notified</narrative> <narrative xml:lang="en">Percentage of people living with HIV and on ART with viral load test result</narrative> <narrative xml:lang="en">TB/HIV-7.1 other: Percentage of people living with HIV newly started on antiretroviral therapy who initiated tuberculosis preventive treatment (TPT) during the reporting period</narrative> <narrative xml:lang="en">Percentage of pregnant women living with HIV who received antiretroviral medicine to reduce the risk of vertical transmission of HIV</narrative> <narrative xml:lang="en">Percentage of new and relapse TB patients tested using WHO recommended rapid diagnostic tests at the time of diagnosis</narrative> <narrative xml:lang="en">HTS-3a-Other 1 Percentage of men most exposed to HIV who were tested for HIV during the reporting period in programs specifically targeting at-risk populations and who know their results</narrative> <narrative xml:lang="en">HTS-3c-Other 1. Percentage of women most exposed to HIV who were tested for HIV during the reporting period in programs specifically targeting at-risk populations and who know their status</narrative> <narrative xml:lang="en">Percentage of adults (15 and above) on ART among all adults living with HIV at the end of the reporting period</narrative> <narrative xml:lang="en">Proportion of suspected malaria cases that receive a parasitological test in the community</narrative> <narrative xml:lang="en">Proportion of pregnant women attending antenatal clinics who received three or more doses of intermittent preventive treatment for malaria</narrative> <narrative xml:lang="en">KP-1a-Other: Percentage of men most exposed to HIV who had access to HIV prevention programs - defined package of services</narrative> <narrative xml:lang="en">Percentage of people living with HIV newly initiated on ART who were screened for TB</narrative> <narrative xml:lang="en">Proportion of suspected malaria cases that receive a parasitological test at public sector health facilities</narrative> <narrative xml:lang="en">Percentage of people who inject drugs reached with HIV prevention programs - defined package of services</narrative> <narrative xml:lang="en">Proportion of confirmed malaria cases that received first-line antimalarial treatment in the community</narrative> <narrative xml:lang="en">KP-1c-Other Percentage of women most at risk of exposure to HIV who had access to HIV prevention programs - defined package of services</narrative> <narrative xml:lang="en">Proportion of infants who received three doses of intermittent preventive treatment for malaria (IPTi)</narrative> <narrative xml:lang="en">Percentage of HIV-exposed infants receiving a virological test for HIV within 2 months of birth</narrative> <narrative xml:lang="en">Number of patients with of all forms of TB notified (i.e., bacteriologically confirmed + clinically diagnosed); *includes only those with new and relapse TB</narrative> <narrative xml:lang="en">Treatment success rate- all forms: Percentage of patients with all forms of TB, bacteriologically confirmed plus clinically diagnosed, successfully treated (cured plus treatment completed) among all TB patients notified during a specified period; *includes only those with new and relapse TB</narrative> <narrative xml:lang="en">Percentage of notified patients with all forms of TB (i.e., bacteriologically confirmed + clinically diagnosed) contributed by non-national TB program providers- community referrals; *includes only those with new and relapse TB</narrative> <narrative xml:lang="en">Percentage of registered new and relapse TB patients with documented HIV status</narrative> <narrative xml:lang="en">Percentage of pregnant women who know their HIV status</narrative> <narrative xml:lang="en">Percentage of people who inject drugs that have received an HIV test during the reporting period in KP-specific programs and know their results</narrative> <narrative xml:lang="en">Percentage of HIV-positive new and relapse TB patients on ART during TB treatment</narrative>